Recently, the journal Nature Biomedical Engineering published a research paper titled “Dendritic-cell-targeting virus-like particles as latent mRNA vaccine carriers” about a new vaccine platform technology that can specifically target dendritic cells (DCs)Read More…
In a first-of-its-kind human clinical trial involving four adult patients, an mRNA cancer vaccine developed by the University of Florida rapidly reprograms the immune system to attack glioblastoma, the most aggressive andRead More…
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the leading cause of cancer-related deaths worldwide. Despite advances in the treatment of advanced hepatocellular carcinoma in recent years,Read More…
Gamma delta (γδ) T cells are a type of innate-like T cell that possess dual anti-tumor activities, capable of directly eliminating tumor cells and acting as immunostimulatory cells to enhance the body’sRead More…
Vaccination is undoubtedly one of the most remarkable health achievements in human history. In just over two centuries, vaccines have enabled us to achieve extraordinary goals, such as eradicating smallpox, eradicating polioRead More…
The development of effective vaccines for infectious diseases is one of the most successful global health interventions ever. Although subunit vaccines largely depend on the selection of antigens and adjuvants, the exposureRead More…
The trend in the field of cancer immunotherapy is the use of cancer vaccines. By using identified tumor antigens to stimulate the immune system, cancer vaccines can generate a specific immune responseRead More…
Recently, researchers from the Wuhan Institute of Virology, Chinese Academy of Sciences, published a research paper titled “Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection” in npjRead More…
Nowadays, immunotherapy has shown great potential in treating human cancer, but it is not effective for all tumor types and only works for less than 3% of pancreatic ductal adenocarcinoma (PDAC) patients.Read More…
Recently, a research paper titled “Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine” was published in Cell Reports Medicine, a sub-journal of Cell.Read More…